NI201300116A - Formulaciones de liberación sostenida de paracetamol - Google Patents

Formulaciones de liberación sostenida de paracetamol

Info

Publication number
NI201300116A
NI201300116A NI201300116A NI201300116A NI201300116A NI 201300116 A NI201300116 A NI 201300116A NI 201300116 A NI201300116 A NI 201300116A NI 201300116 A NI201300116 A NI 201300116A NI 201300116 A NI201300116 A NI 201300116A
Authority
NI
Nicaragua
Prior art keywords
paracetamol
sustained release
release formulations
release phase
unique
Prior art date
Application number
NI201300116A
Other languages
English (en)
Inventor
Valenti Buan Carla
Liu Dongzhou
Meghpara Kanji
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of NI201300116A publication Critical patent/NI201300116A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presente está dirigida a una composición farmacéutica de liberación sostenida de dos veces al día de paracetamol que tiene una fase de liberación inmediata de paracetamol y una fase de liberación sostenida de paracetamol, dicha composición tiene propiedades farmacocinéticas únicas y ventajosas y una composición farmacéutica que comprende sólo una fase de liberación sostenida de paracetamol que tiene propiedades farmacocinéticas únicas y ventajosas.
NI201300116A 2011-05-06 2013-11-04 Formulaciones de liberación sostenida de paracetamol NI201300116A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161483320P 2011-05-06 2011-05-06

Publications (1)

Publication Number Publication Date
NI201300116A true NI201300116A (es) 2014-11-13

Family

ID=47139543

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300116A NI201300116A (es) 2011-05-06 2013-11-04 Formulaciones de liberación sostenida de paracetamol

Country Status (19)

Country Link
US (1) US20140065213A1 (es)
EP (1) EP2704697B1 (es)
CN (1) CN103648486A (es)
AP (1) AP3878A (es)
AU (1) AU2012253834B2 (es)
BR (1) BR112013028668A2 (es)
CA (1) CA2835330A1 (es)
CL (1) CL2013003176A1 (es)
CO (1) CO6801767A2 (es)
CR (1) CR20130572A (es)
DO (1) DOP2013000258A (es)
EA (1) EA201391643A1 (es)
GT (1) GT201300270A (es)
MX (1) MX2013012918A (es)
NI (1) NI201300116A (es)
SG (1) SG194605A1 (es)
TW (1) TW201306881A (es)
WO (1) WO2012154563A1 (es)
ZA (1) ZA201308316B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR096223A1 (es) * 2013-05-10 2015-12-16 Glaxosmithkline Llc Pastilla de nicotina para administración oral
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
DK3265126T3 (da) 2015-03-03 2021-09-13 Saniona As Kombinationsformulering af tesofensin og metoprolol
BE1023116B1 (nl) * 2015-07-24 2016-11-23 Nordic Specialty Pharma Bvba Paracetamol omvattend preparaat met vertraagde en aanhoudende afgifte

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN940796A0 (en) * 1996-04-23 1996-05-16 F.H. Faulding & Co. Limited Taste masked pharmaceutical compositions
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
SK285250B6 (sk) * 1998-10-01 2006-09-07 Novartis Ag Orálna farmaceutická kompozícia obsahujúca rivastigmín a použitie rivastigmínu
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
WO2004004696A1 (en) * 2002-07-05 2004-01-15 Temrel Inc. Controlled release composition
JP5563731B2 (ja) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン オピオイドおよび非オピオイド鎮痛薬の制御放出製剤
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
PT1781277E (pt) * 2004-07-07 2012-05-07 Aft Pharmaceuticals Ltd Composição combinada
WO2009100118A1 (en) * 2008-02-01 2009-08-13 Abbott Laboratories Extended release hydrocodone acetaminophen and related methods and uses thereof
MX2010009990A (es) * 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
MX339867B (es) * 2008-10-27 2016-06-14 Alza Corp * Forma de dosificacion oral de liberacion prolongada de acetaminofeno/tramadol.
US8021420B2 (en) * 2009-03-12 2011-09-20 Medtronic Vascular, Inc. Prosthetic valve delivery system
KR20120059582A (ko) * 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물

Also Published As

Publication number Publication date
AP2013007224A0 (en) 2013-11-30
CN103648486A (zh) 2014-03-19
EP2704697B1 (en) 2018-09-12
NZ617198A (en) 2016-01-29
AP3878A (en) 2016-10-31
CR20130572A (es) 2014-03-20
CA2835330A1 (en) 2012-11-15
GT201300270A (es) 2014-12-16
EA201391643A1 (ru) 2014-07-30
TW201306881A (zh) 2013-02-16
ZA201308316B (en) 2014-07-30
AU2012253834B2 (en) 2016-06-16
MX2013012918A (es) 2013-11-21
CL2013003176A1 (es) 2014-07-04
BR112013028668A2 (pt) 2017-01-24
EP2704697A1 (en) 2014-03-12
CO6801767A2 (es) 2013-11-29
AU2012253834A1 (en) 2013-12-05
US20140065213A1 (en) 2014-03-06
SG194605A1 (en) 2013-12-30
WO2012154563A1 (en) 2012-11-15
EP2704697A4 (en) 2015-01-07
DOP2013000258A (es) 2014-07-15

Similar Documents

Publication Publication Date Title
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
BR112013007362A2 (pt) composição farmacêutica
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
MY163083A (en) Solid forms of a pharmaceutically active substance
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015009228A2 (pt) soluções estáveis anti-inflamatórias e midriáticas livres de conservantes para injeção
GT201200284A (es) Composición farmacéutica
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112015006731A2 (pt) combinações e usos das mesmas
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201100286A1 (ru) Композиция кветиапина
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
NI201300116A (es) Formulaciones de liberación sostenida de paracetamol
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CO7131388A2 (es) Métodos de quelatos de oligonucleótidos
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
CY1121696T1 (el) Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης
EP2999461A4 (en) Targeted delivery of drugs to the myometrium
AU2014271207A1 (en) Targeted delivery of drugs to the myometrium
MX2012008253A (es) Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.